Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation.
Barsouk A, Friedes C, Iocolano M, Doucette A, Cohen RB, Robinson KW, D'Avella CA, Marmarelis ME, Kosteva JA, Singh AP, Ciunci CA, Levin WP, Cengel KA, Bradley JD, Feigenberg SJ, Sun L, Aggarwal C, Langer CJ, Yegya-Raman N. Barsouk A, et al. Among authors: feigenberg sj. Clin Lung Cancer. 2024 May;25(3):e161-e171. doi: 10.1016/j.cllc.2023.12.009. Epub 2023 Dec 22. Clin Lung Cancer. 2024. PMID: 38195320
Pneumonitis Rates Before and After Adoption of Immunotherapy Consolidation in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation.
Yegya-Raman N, Friedes C, Lee SH, Iocolano M, Duan L, Wang X, Li B, Aggarwal C, Cohen RB, Su W, Doucette A, Levin WP, Cengel KA, DiBardino D, Teo BK, O'Reilly SE, Sun L, Bradley JD, Xiao Y, Langer CJ, Feigenberg SJ. Yegya-Raman N, et al. Among authors: feigenberg sj. Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1445-1454. doi: 10.1016/j.ijrobp.2023.08.039. Epub 2023 Aug 22. Int J Radiat Oncol Biol Phys. 2024. PMID: 37619788
Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer.
Yegya-Raman N, Berman AT, Ciunci CA, Friedes C, Berlin E, Iocolano M, Wang X, Lai C, Levin WP, Cengel KA, O'Reilly SE, Cohen RB, Aggarwal C, Marmarelis ME, Singh AP, Sun L, Bradley JD, Plastaras JP, Simone CB 2nd, Langer CJ, Feigenberg SJ. Yegya-Raman N, et al. Among authors: feigenberg sj. Int J Radiat Oncol Biol Phys. 2024 May 1;119(1):56-65. doi: 10.1016/j.ijrobp.2023.08.047. Epub 2023 Aug 29. Int J Radiat Oncol Biol Phys. 2024. PMID: 37652303 Clinical Trial.
Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression.
Friedes C, Yegya-Raman N, Zhang S, Iocolano M, Cohen RB, Aggarwal C, Thompson JC, Marmarelis ME, Levin WP, Cengel KA, Ciunci CA, Singh AP, D'Avella C, Davis CW, Langer CJ, Feigenberg SJ. Friedes C, et al. Among authors: feigenberg sj. Clin Lung Cancer. 2024 Jan;25(1):50-60.e6. doi: 10.1016/j.cllc.2023.09.002. Epub 2023 Sep 17. Clin Lung Cancer. 2024. PMID: 37813713
159 results